As we look towards 2025, the conversation around Artificial Intelligence safety isn't just a whisper; it's becoming a robust dialogue, and the UK is right in the thick of it. It’s easy to get lost in the sheer pace of AI development, but understanding the safety nets being woven is crucial for all of us.
Internationally, a significant milestone is the "International AI Safety Report 2025." Imagine this as the first truly comprehensive global deep-dive into what advanced AI can do and, more importantly, what risks it might pose. Spearheaded by a luminary like Turing-award winner Yoshua Bengio, it’s the product of 100 AI experts from around the world, aiming to build a common ground on understanding these complex challenges. With an advisory panel boasting representatives from 30 countries, the UN, EU, and OECD, this report is set to be a foundational piece for global AI governance.
Closer to home, or rather, across the pond, the U.S. AI Safety Institute Consortium (AISIC) held its first in-person plenary in December 2024. This gathering wasn't just a look back at 2024's progress but a forward-thinking session to map out research priorities for 2025. What struck me here is the sheer scale of their consortium – over 290 member companies, organizations, and even local governments. They're the ones on the ground, building and using these advanced systems, and their collective effort to bridge the gap between industry, academia, civil society, and the government is vital. Their focus is on understanding how to truly harness AI's benefits while keeping those potential risks firmly in check.
And then there's the more immediate, tangible side of safety, particularly in healthcare. The MHRA (Medicines and Healthcare products Regulatory Agency) in the UK released its December 2025 Safety Roundup. This isn't about abstract AI risks; it's about the practical safety of medicines and medical devices. For instance, they highlighted a very rare but serious side effect, idiopathic intracranial hypertension (IIH), associated with the drug mesalazine. The advice is clear: patients should be aware of the symptoms – severe headaches, visual disturbances – and healthcare professionals need to remain vigilant. It’s a stark reminder that even as we push the boundaries of AI, ensuring the safety of existing medical treatments remains paramount.
Another point from the MHRA roundup that caught my eye was the transition to a new formulation of Rybelsus® (semaglutide tablets). The concern here is medication error during the switch, which could lead to overdose or underdose, impacting disease control and increasing side effects. This underscores the need for coordinated healthcare system responses and clear communication to professionals and patients alike.
So, as 2025 dawns, the UK's AI safety landscape is a multi-faceted picture. It involves global collaboration on the cutting edge of AI, robust domestic efforts to bridge research and application, and a continued, unwavering focus on the safety of everyday medical treatments. It’s a complex, evolving space, but one where proactive measures and open dialogue are key to ensuring AI benefits us all, safely.
